Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
27.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
|
|
|
|
|
2.99
|
|
|
|
|
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.